The Pd-Pt-GOx/HA system specifically targets CD44-overexpressed cancer cells and possesses intracellular Hyase-responsive GO, catalase (CAT), and peroxidase (POD)-like activities as well as glutathione (GSH) oxidation capacity, significantly enhancing therapeutic efficacy and biosafety. The gene discussed is CD44; the disease is cancer.